Y-Mabs Therapeutics Inc

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation featuring interim clinical data on naxitamab, a recombinant, humanized anti-GD2 monoclonal antibody, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”) will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting to be held June 2-6, 2023, in Chicago, Illinois.

Y-mAbs Announces Presentation of Naxitamab Data at ASCO

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation featuring the design of its Phase 1 clinical trial, evaluating the Company's Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy (“SADA Y-PRIT”) Theranostic Platform for the treatment of certain GD2-positive solid tumors, including small cell lung cancer, sarcoma and malignant melanoma will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting to be held June 2-6, 2023 in Chicago, Illinois.

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (“Anvisa”) has granted marketing authorization for DANYELZA (naxitamab-gqgk) 40mg/10mL injection. DANYELZA will be marketed in Brazil by Y-mAbs' partner Adium Pharma S.A. (“Adium”).

Y-mAbs' DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants Thomas Gad - Founder, President, Interim Chief Executive Officer Sue Smith - Senior Vice President and Chief Commercial Officer Vignesh Rajah - Senior Vice President and Chief Medical Officer Bo Kruse - Chief Financial Officer, Treasurer, and Secretary Conference Call Participants William Maughan - Canaccord Genuity Mike Ulz - Morgan Stanley Charles Zhu - Guggenheim Securities Tessa Romero - JP Morgan David Nierengarten - Wedbush Securities Operator Good morning, and welcome to the Y-mAbs Therapeutics, Inc.'s Earnings Call for the First Quarter of 2023. At this time, all participants are in a listen-only mode.

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2023 Earnings Call Transcript

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.64 per share a year ago.

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the first quarter of 2023.

Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

Y-mAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know

NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, May 9, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commerical Officer and Vignesh Rajah, Chief Medical Officer.

Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

The consensus price target hints at an 111.1% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Y-mAbs Therapeutics, Inc. (YMAB) Could Rally 111.13%: Here's is How to Trade

Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q4 2022 Earnings Conference Call March 31, 2023 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO & President Sue Smith - SVP & Chief Commercial Officer Bo Kruse - EVP, Secretary, Treasurer & CFO Vignesh Rajah - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Etzer Darout - BMO Capital Markets William Maughan - Canaccord Genuity Taylor Hanley - JPMorgan Edouard Mullarky - Guggenheim Securities Operator Good morning, and welcome to the Y-mAbs Therapeutics, Inc.'s Earnings Call for the Fourth Quarter 2022. [Operator Instructions] As a reminder, today's conference will be recorded.

Y-mAbs Therapeutics, Inc. (YMAB) Q4 2022 Earnings Call Transcript

Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 106.82% and 50.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates

NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the fourth quarter and full year 2022.

Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December 31, 2022, on Thursday, March 30, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, March 31, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commerical Officer and Vignesh Rajah, Chief Medical Officer.

Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023

NEW YORK , March 20, 2023 /PRNewswire/ -- Attention Y-mAbs Therapeutics, Inc. ("Y-mAbs") (NASDAQ: YMAB) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020 through October 28, 2022, inclusive.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK , March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) and reminds investors of the March 20, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Y-mAbs stock or options between October 6, 2020 and October 28, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 20, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) common stock between October 6, 2020 and October 28, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

NEW YORK , March 17, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/y-mabs-therapeutics-inc-loss-submission-form/?id=37347&from=4 This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020 through October 28, 2022, inclusive.

YMAB SHAREHOLDER ALERT: Jakubowitz Law Reminds Y-mAbs Shareholders of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK , March 16, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Y-mAbs investors who were adversely affected by alleged securities fraud.

YMAB LAWSUIT ALERT: Levi & Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

LOS ANGELES, CA / ACCESSWIRE / March 15, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or "the Company") (NASDAQ:YMAB) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 6, 2020 and October 28, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before March 20, 2023.

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , March 15, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) between October 6, 2020 and October 28, 2022, both dates inclusive (the "Class Period"), of the important March 20, 2023 lead plaintiff deadline. SO WHAT: If you purchased Y-mAbs securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 20 Deadline in Securities Class Action - YMAB

BENSALEM, Pa. , March 15, 2023 /PRNewswire/ -- Law Offices of Howard G.

YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud Lawsuit

Did you lose money on investments in Y-mAbs Therapeutics?  If so, please visit Y-mAbs Therapeutics, Inc. Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

NEW YORK , March 14, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) alleging that the Company violated federal securities laws. This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020 through October 28, 2022, inclusive.Lead Plaintiff Deadline: March 20, 2023 No obligation or cost to you.

YMAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 20, 2023 in the Class Action Filed on Behalf of Y-mAbs Therapeutics, Inc. Shareholders

LOS ANGELES, CA / ACCESSWIRE / March 13, 2023 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or "the Company") (NASDAQ:YMAB) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 6, 2020 and October 28, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before March 20, 2023.

News for Y-Mabs Therapeutics Inc Stock (YMAB)